Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide maintenance after allogeneic stem cell transplantation for high-risk acute myeloid leukemia
ChiCTR2300067742Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in acute myeloid leukemia (AML), sponsored by West China Hospital of Sichuan University. Primary endpoints: Relapse rate and Progression-free survival. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300067742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067742.